A Phase 2, Open-label, Single-arm Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Trial Profile

A Phase 2, Open-label, Single-arm Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Leukaemia; Multiple myeloma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Apr 2014 New source identified and integrated (Mayo Clinic; 13-001585).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top